Top

Published in:

01-04-2014 | Clinical Study

Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature

Authors: Yasuo Iwadate, Akiko Suganami, Shiro Ikegami, Natsuki Shinozaki, Tomoo Matsutani, Yutaka Tamura, Naokatsu Saeki, Ryuya Yamanaka

Published in: Journal of Neuro-Oncology | Issue 2/2014

Abstract

The survival of patients with primary CNS lymphoma (PCNSL) has been improved by high-dose methotrexate (HD-MTX). Since the combination therapy of HD-MTX and whole-brain radiotherapy (WBRT) carries a significant risk for delayed neurotoxicity, it is important to know the therapeutic potential and prognostic factors for HD-MTX without WBRT. We retrospectively reviewed 46 consecutive patients with PCNSL treated with a HD-MTX (3.5 g/m²) and deferred WBRT. Patients who achieved complete response or partial response after three courses of HD-MTX were cautiously followed-up without additional treatment. Patients who had either stable disease, progressive disease, or disease relapse were offered salvage therapy. The median progression-free survival period was 10 months and the median overall survival period was 52 months, with a 5-year survival rate of 39 %. Nineteen patients (49 % of the evaluable patients) achieved a complete response at the initial response assessment. Involvement of deep structures of the brain (corpus callosum, basal ganglia and brainstem) was significantly associated with the worse progression-free survivals (p = 0.0058) and overall survivals (p = 0.0177). Gene expression profiling analysis by microarray was compared in eight patients between PCNSLs located in the deep structures of the brain and non-deep-seated tumors. The result showed that up-regulation of signal transduction-related genes and down-regulation of catalytic activity-related genes in the non-deep-seated PCNSL compared with the deep-seated tumors. The present study shows that PCNSL located in non-deep structures of the brain responds better to HD-MTX alone than those involved deep-structures.

Hochberg FH, Baehring JM, Hochberg EP (2007) Primary CNS lymphoma. Nat Clin Prac 3:24–35CrossRef

Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555PubMedCrossRef

Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595–1600PubMedCrossRef

DeAngelis L, Posner JB (2009) Side effects of radiation therapy. In: Neurologic complications of cancer, 2nd edn. Oxford University Press, New York, pp 551–555

Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD (2007) Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 62:515–520PubMedCrossRef

Freilich RJ, Delattre JY, Monjour A, DeAngelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435–439PubMedCrossRef

Cher L, Glass J, Harsh GR, Hochberg FH (1996) Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46:1757–1759PubMedCrossRef

Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Bogdhan B, European Organization for Research and Treatment of Cancer Brain Tumor Group (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726–2731PubMedCrossRef

Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489–4495PubMedCrossRef

10.

Gavrilovic IT, Hormingo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574PubMedCrossRef

11.

Gerard LM, Imarie KR, Mangel J, Buckstein R, Doherty M, Mackenzie R, Cheung MC (2011) High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma. Leuk Lymphoma 52:1882–1890PubMedCrossRef

12.

Guha-Thakurta N, Damek D, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259–268PubMedCrossRef

13.

Herrlinger U, Kuker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M, Neuro-Oncology Working Group of the German Society (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843–847PubMedCrossRef

14.

Gerstner ER, Carson KA, Grossman SA, Batchelor TT (2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70:401–402PubMedCrossRef

15.

Cobert J, Hochberg E, Woldenberg N, Hochberg F (2009) Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort. J Neurooncol 98:385–393PubMedCentralPubMedCrossRef

16.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomized, non-inferiority trial. Lancet Oncol 11:1036–1047PubMedCrossRef

17.

Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Poortmans P, Armitag JO, Cavalli F, International Primary CNS Lymphoma Collaborative Group (2005) Report of an international workshop on standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043PubMedCrossRef

18.

Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, Taki T, Sato M, Aozasa K, Yoshimine T (1999) Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91:221–230PubMedCrossRef

19.

Ferreri AJM, Blay J-Y, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272PubMedCrossRef

20.

Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL (1989) Prognosic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63:939–947PubMedCrossRef

21.

Michalski JM, Garcia DM, Kase E, Gringsby PW, Simpson JR (1990) Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure. Radiology 176:855–860PubMed

22.

Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T et al (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716–3723PubMedCentralPubMedCrossRef

23.

Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W et al (2008) Gene expression profiling suggests primary cenral nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22:400–405PubMedCrossRef

24.

Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P et al (2008) Pathway analysis of primary central nervous system lymphoma. Blood 111:3200–3210PubMedCentralPubMedCrossRef

25.

Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH et al (2011) Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 117:1291–1300PubMedCrossRef

26.

Kawaguchi A, Iwadate Y, Komohara Y, Sano M, Kajiwara K et al (2012) Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res 18:5672–5681PubMedCrossRef

27.

Carrabba MG, Reni M, Foppoli M, Chiara A, Franzin A et al (2010) Tretament approach for primary CNS lymphomas. Expert Opin Pharmacother 11:1263–1276PubMedCrossRef

Title: Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature
Authors: Yasuo Iwadate
Akiko Suganami
Shiro Ikegami
Natsuki Shinozaki
Tomoo Matsutani
Yutaka Tamura
Naokatsu Saeki
Ryuya Yamanaka
Publication date: 01-04-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1379-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Rathke’s cleft cysts: review of natural history and surgical outcomes

The feasibility of frameless stereotactic radiosurgery in the management of pediatric central nervous system tumors

Natural history of cavernous malformations in children with brain tumors treated with radiotherapy and chemotherapy

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

Significance of histology in determining management of lesions regrowing after radiosurgery

Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade